[182 Pages Report] The Plasma Fractionation Market size was estimated at USD 35.52 billion in 2023 and expected to reach USD 38.95 billion in 2024, at a CAGR 10.45% to reach USD 71.27 billion by 2030.

Plasma fractionation refers to collecting, separating, and purifying various essential components present in human plasma, primarily including albumin, immunoglobulins, coagulation factors, and other proteins. These components have many applications in medical treatments, such as hemophilia therapy, immunity disorders treatment, wound healing support, neurology therapy, and other rare diseases. The demand for source plasma has been steadily increasing due to its role as a vital ingredient in several life-saving therapies. This surge can be attributed to an aging population prone to chronic illnesses requiring blood-based therapies and the rising prevalence of immune disorders. In addition, rising awareness about blood-related diseases among patients contributes significantly to this market’s expansion. However, stringent government regulations on plasma fractionation and the presence of alternative recombinant therapies may hamper the market demand. New advancements in production technology further boost opportunities for the players involved in this field. Moreover, strategic collaborations among various stakeholders drive innovative research work within the industry that provides novel solutions and is expected to create a lucrative market opportunity in the forecasted period.

Regional Insights

The Americas has a significant market presence in the plasma fractionation market due to a well-established healthcare infrastructure, high prevalence of immunodeficiency diseases, and an increasing geriatric population. In Europe, EU countries have a strong regulatory framework governing the plasma fractionation industry. The European Medicines Agency (EMA) regulates manufacturing practices and oversees quality standards for blood-derived products, significantly driving the region’s market demand. The MEA region presents lucrative opportunities due to rising incomes and expanding access to healthcare services. The Asia-Pacific observed a developing landscape in the plasma fractionation market owing to rapid urbanization and economic development that is driving investments in healthcare infrastructure. Additionally, there is an increasing focus on blood safety regulations by governments in the APAC region, presenting opportunities for market players.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Plasma Fractionation Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Plasma Fractionation Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Plasma Fractionation Market, highlighting leading vendors and their innovative profiles. These include 3M Company, ADMA Biologics, Inc., Bharat Serums and Vaccines Limited, Bio Products Laboratory Ltd., Biotest AG by Grifols, S.A., China Biologic Products, Inc., CSL Limited, Emergent BioSolutions Inc., Fusion Health Care Pvt. Ltd., GC Biopharma corp., Grifols, S.A., HEINKEL Process Technology GmbH, Hemarus Therapeutics Ltd, Intas Pharmaceuticals Ltd., Kamada Ltd., Kedrion S.p.A., LFB SA, Merck KGaA, Octapharma AG, PlasmaGen BioSciences Pvt. Ltd., Prothya Biosolutions B.V., Sanquin, Shanghai Raas Blood Products Co. Ltd, SK Plasma Co.,Ltd., STERIS plc, and Takeda Pharmaceutical Company Ltd.

Market Segmentation & Coverage

This research report categorizes the Plasma Fractionation Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Albumin
    • Coagulation Factor Concentrates
      • Factor IX
      • Factor VIII
      • Factor XIII
      • Fibrinogen Concentrates
      • Prothrombin Complex Concentrate
      • Von Willebrand Factor
    • Immunoglobulin
      • Intravenous Immunoglobulin
      • Subcutaneous Immunoglobulin
    • Protease Inhibitors
  • Application
    • Critical Care
    • Hemato-Oncology
    • Hematology
    • Neurology
    • Pulmonology
    • Rheumatology
  • End-User
    • Academic & Research Institutes
    • Clinical Research Laboratories

  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Plasma Fractionation Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Plasma Fractionation Market?
  3. What are the technology trends and regulatory frameworks in the Plasma Fractionation Market?
  4. What is the market share of the leading vendors in the Plasma Fractionation Market?
  5. Which modes and strategic moves are suitable for entering the Plasma Fractionation Market?